Technology and nature merging in a human heart, representing balance in cardiac treatment.

New Anticoagulants: Are They Right for Your Heart?

Beau Callahan in Health & Wellness August 2025 • 4 min read.

"Understanding adherence to newer oral anticoagulants for atrial fibrillation and what it means for your health."

Atrial fibrillation (AFib) is a common heart condition that increases your risk of stroke. For years, warfarin was the go-to medication to prevent strokes in AFib patients. However, managing warfarin can be tricky due to its unstable effects, requiring frequent monitoring and dose adjustments.

Newer oral anticoagulants (NOACs) have emerged as an alternative. These medications offer the convenience of fixed doses and eliminate the need for regular blood tests. But how well are patients adopting NOACs, and what factors influence their use? Understanding these aspects is crucial for effective stroke prevention.

This article will explore a study that delved into the use of NOACs among patients with AFib. We'll uncover the reasons behind patient choices, the challenges in treatment adherence, and what this means for your heart health.

NOACs vs. Warfarin: What Influences Patient Choice?

Technology and nature merging in a human heart, representing balance in cardiac treatment.

A study, conducted using data from the PROFILE registry, aimed to assess how frequently patients with atrial fibrillation were prescribed NOACs and to identify the factors influencing their acceptance of these newer medications. The study involved 111 patients with AFib who visited a cardiology center between 2013 and 2014. All were given information about NOACs, including their cost, convenience, advantages over warfarin, and potential side effects.

The results revealed some interesting trends in patient preferences:

Of those willing to take NOACs, about 41% ultimately declined the medication.
The most common reasons for not taking NOACs were satisfaction with warfarin (32.6%) and the high cost of NOACs (23.9%).
Other factors included concerns about potential side effects listed in the medication instructions (15.2%) and recommendations from other doctors to discontinue NOACs (8.7%).
Patients already receiving preferential medication benefits and those taking warfarin at the start of the study were less likely to switch to NOACs.

On the other hand, patients who were taking NOACs showed a greater awareness of the potential outcomes of their condition, were more knowledgeable about the possible side effects of anticoagulants, and were more likely to read the medication instructions.

Key Takeaways: What You Need to Know About NOACs and AFib

This study highlights that while many AFib patients are open to using NOACs, several factors can influence their decision. Cost remains a significant barrier for some, while others are comfortable with their existing warfarin treatment. It's essential to have open conversations with your doctor about your preferences, concerns, and financial considerations to determine the most suitable treatment for you.

If you're currently taking warfarin, it's worth discussing the potential benefits and drawbacks of switching to a NOAC with your physician. Factors to consider include your individual risk of bleeding, the convenience of not requiring regular blood tests, and your ability to afford the medication.

Ultimately, the best treatment plan is one that you're comfortable with and can adhere to consistently. By being informed and actively involved in your healthcare decisions, you can take control of your heart health and reduce your risk of stroke.

About this Article -

This article was crafted using a human-AI hybrid and collaborative approach. AI assisted our team with initial drafting, research insights, identifying key questions, and image generation. Our human editors guided topic selection, defined the angle, structured the content, ensured factual accuracy and relevance, refined the tone, and conducted thorough editing to deliver helpful, high-quality information.See our About page for more information.

Everything You Need To Know

What are newer oral anticoagulants (NOACs), and what are some factors influencing patient decisions regarding their use for atrial fibrillation (AFib)?

Newer oral anticoagulants, or NOACs, offer advantages over warfarin, like fixed doses and no need for regular blood tests. However, a PROFILE registry study showed that even when patients are open to NOACs, many decline them. Cost is a big factor, as is satisfaction with existing warfarin treatment. Other concerns include potential side effects and advice from other doctors.

According to the PROFILE registry study, what were the primary reasons patients declined to take NOACs despite being informed about them?

The PROFILE registry study found several reasons. Many patients were happy with their current warfarin treatment or were concerned about the higher cost of NOACs. Some were worried about potential side effects listed in the medication instructions, while others were advised by different doctors to stop using NOACs.

What patient characteristics, as identified in the PROFILE registry study, made individuals less likely to switch from warfarin to NOACs?

The PROFILE registry study indicated that patients already receiving preferential medication benefits or those already taking warfarin were less inclined to switch to NOACs. This suggests that existing routines and financial support significantly influence treatment decisions.

What did the PROFILE registry study reveal about the characteristics of patients who were already taking NOACs for atrial fibrillation?

Patients taking NOACs, according to the PROFILE registry study, displayed a greater awareness of potential health outcomes and were more knowledgeable about the side effects of anticoagulants. They were also more likely to read medication instructions. This suggests that informed patients are more engaged with their treatment.

What aspects of anticoagulant treatment for atrial fibrillation (AFib) were not covered in the PROFILE registry study, and what further research could be conducted?

The PROFILE registry study did not delve into the specifics of how doctors present NOACs versus warfarin or the detailed reasons behind doctors' recommendations to discontinue NOACs. Future research could explore the communication strategies used by healthcare providers and the specific clinical scenarios that prompt switches or discontinuations of anticoagulant medications. Further investigation could explore long-term adherence rates and clinical outcomes associated with both NOACs and warfarin.